Macular disease - AMD

More details of a proposed $11 million-a-year ‘Neovascular AMD treatment incentive program’ that would financially encourage more ophthalmologists to bulk...

Melbourne biopharmaceutical company Opthea has abandoned efforts to develop its therapy sozinibercept for neovascular age-related macular degeneration (nAMD), with a...

Researchers at the National Institutes of Health (NIH) in the United States say they have developed eye drops that extend...

Melbourne biopharmaceutical firm Opthea has failed to meet the primary end point in a pivotal Phase 3 trial of its...

Optos will have a strong presence on the Australian ophthalmic events circuit in 2025, providing a key opportunity for eyecare...

The Federal Government is deferring the controversial private health insurance reclassification of intravitreal injections for another 12 months and will...

In what is expected to be great news for about 20,000 Australians, ophthalmologists are now able to prescribe the first...

Macular Disease Foundation Australia (MDFA) is calling on the next Federal Government to allow bulk billing of eye injections for...

Approval of the first therapy for geographic atrophy (GA), Syfovre (pegcetacoplan), is being hailed a “landmark moment” for the the...

Four eye research projects have secured more than $8 million in funding in the 2025 National Health and Medical Research...